RxDoctor Payments Data

Kevin Wieczenski

Family · Fonda, NYNPI 1811674278

Payments from drug & device makers

$1,369in general payments, 2019–2025

Across 67 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$258
  • Novo Nordisk$189
  • AbbVie$186
  • AstraZeneca$170
  • Boehringer Ingelheim$107
  • Amgen$80
  • plus $380 from 8 others

What the payments were for

  • Food & beverage$1,369100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,369 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$15,888
Medicare patients
82
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$46,252
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$36,620
MounjaroTirzepatide26$30,185
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$25,419
XareltoRivaroxaban17$22,035
FarxigaDapagliflozin Propanediol16$21,334
OzempicSemaglutide20$20,603
TrulicityDulaglutide16$19,024
JardianceEmpagliflozin17$18,825
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,248
Levothyroxine Sodium139$2,948
Atorvastatin Calcium225$2,719
Albuterol Sulfate HfaAlbuterol Sulfate81$2,225
Hydroxyzine Hcl15$1,823
Rosuvastatin Calcium101$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$258$49,20842 claims
AstraZenecaBreztri Aerosphere, Farxiga$170$46,75356 claims
PfizerEliquis$75$46,25235 claims
GSKTrelegy Ellipta$35$36,62054 claims
Novo NordiskOzempic$189$20,60320 claims
Boehringer IngelheimJardiance$107$18,82517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Fonda

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →